TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02801305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Ointment 2%
Description: This a topical agent which will be applied on digital ulcers by scleroderma patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: This is used as the topical placebo agent.
Study: NCT00876746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular vs. Infraclavicular ropivicaine infusion
Description: Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
Study: NCT04045119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Moisturizer
Description: The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
Study: NCT03720340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Interleukin-11
Description: Recombinant Human Interleukin-11 was administed through respiratory tract.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline was administed through respiratory tract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline was administed through respiratory tract
Study: NCT02374957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: 100 mg twice daily for 90 days
Study: NCT03751878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of reporting inconsistencies
Description: 1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Peer Review.
Description: Manuscripts will undergo the usual peer review process.
Study: NCT03532178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline
Description: The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;
Description: The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period.
Study: NCT02774252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
Study: NCT02228278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals.

Intervention type: OTHER
Group type: OTHER
Intervention: Group B
Description: Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals.
Study: NCT02342561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ioban 2 incision drape, 3M
Description: The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
Study: NCT01729598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: generic valproic acid tablets packaged in placebo-matched capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule without active study medication in identical capsules as experimental medicine.
Study: NCT03014219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Only 1 arm: treatment with MSC-AFP
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
Study: NCT02583789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral treprostinil
Description: Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral treprostinil
Description: Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
Study: NCT03841149

Intervention type: OTHER
Intervention: Ultrasound Imaging
Description: 3D volume calculation using on-line and off-line softwares
Study: NCT04159012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4).
Study: NCT04090073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: As above

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track Perioperative program
Description: As above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast-track Perioperative program
Description: As above
Study: NCT00999284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK200775
Description: Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Intravenous infusion of sodium chloride over a period of 4 hours.
Study: NCT01878513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 3 levels of dosing dependent on which condition a patient is assigned to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 3 levels of dosing dependent on which condition a patient is assigned to.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 3 levels of dosing dependent on which condition a patient is assigned to.
Study: NCT03113435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen consumption optimization
Description: hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen consumption optimization
Description: hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
Study: NCT01845064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Study: NCT01484132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration of dental caries with dental composite
Description: Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
Study: NCT02490410

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein supplement
Study: NCT02490410

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein supplement
Study: NCT03819673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group Care
Description: children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
Study: NCT03830775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Description: PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)
Study: NCT04497207

Intervention type: OTHER
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.

Intervention type: OTHER
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
Study: NCT02946983

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intragastric administration of distilled water
Study: NCT03771235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention for Tics
Description: Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
Study: NCT04060238

Intervention type: DIAGNOSTIC_TEST
Intervention: Anomaloscope (colour vision test)
Description: The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)
Study: NCT03771235

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tic Information and Coping Strategies
Description: Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
Study: NCT01970943

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be compared to No Intervention.
Study: NCT04497207

Intervention type: OTHER
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
Study: NCT00835822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venocur Triplex®
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Study: NCT02493790

Intervention type: OTHER
Intervention: Cognitive and motor performances

Intervention type: OTHER
Intervention: Cognitive and motor performances
Study: NCT02808650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic (PK) study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Given IV
Study: NCT03225274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises as Therapeutic Play
Description: On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.
Study: NCT02044835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu-zheng-qu-zhuo oral liquid
Description: Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
Study: NCT03630367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intramuscular injection 8 mg
Study: NCT03117972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: Maintenance chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2
Description: Maintenance chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Maintenance chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Maintenance chemotherapy
Study: NCT01568905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level nicotine cigarette
Description: smoke the study cigarette exclusively for one week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate nicotine level cigarette
Description: smoke the study cigarette exclusively for one week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High level nicotine cigarette
Description: smoke the study cigarette exclusively for one week
Study: NCT01845064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03630367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intramuscular injection 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine 1G/5mL Injection
Description: slow intravenous injection
Study: NCT04598464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise
Description: The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
Study: NCT00892658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
Study: NCT03637179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT01419639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001) , Afinitor®
Description: Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
Study: NCT01672736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7487, Velcade, Dexamethasone
Description: ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration